Search research articles
Contact Us
Filters
Showing results (31-40 of 124) with videos related to
Page
of 13
Sort By:
Gynecologic Oncology
|
June 12, 2016
Since surgery isn't getting any easier, why is reimbursement going down? An update from the SGO taskforce on coding and reimbursement
Shitanshu Uppal, Mark S Shahin, Jill A Rathbun, et al.
Journal of Gynecologic Oncology
|
June 23, 2016
Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
Jovana Y Martin, Renata R Urban, John B Liao, et al.
Gynecologic Oncology
|
October 4, 2016
SGO Health Policy and Socioeconomic Committee: Current and Future Efforts of the Coding and Reimbursement Taskforce and the Policy, Quality and Outcomes Taskforce
Barbara A Goff, Mark S Shahin, Matthew A Powell, et al.
JAMA
|
June 10, 2004
Frequency of symptoms of ovarian cancer in women presenting to primary care clinics
Barbara A Goff, Lynn S Mandel, Cindy H Melancon, et al.
Journal of Minimally Invasive Gynecology
|
January 24, 2018
Robotic, Laparoscopic, or Open Hysterectomy: Surgical Outcomes by Approach in Endometrial Cancer
Tiffany L Beck, Melissa A Schiff, Barbara A Goff, et al.
Gynecologic Oncology
|
April 13, 2011
Patterns of spread and recurrence of sex cord-stromal tumors of the ovary
Melissa M Thrall, Pamela Paley, Ellen Pizer, et al.
American Journal of Obstetrics and Gynecology
|
June 26, 2003
Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602)
Barbara A Goff, Tove Thompson, Benjamin E Greer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 22, 2016
Evaluation of a Validated Biomarker Test in Combination With a Symptom Index to Predict Ovarian Malignancy
Renata R Urban, Alan Smith, Kathy Agnew, et al.
Integrative Cancer Therapies
|
April 30, 2013
Adverse events associated with complementary and alternative medicine use in ovarian cancer patients
Erin S Sweet, Leanna J Standish, Barbara A Goff, et al.
Gynecologic Oncology
|
December 7, 2017
The end of life costs for Medicare patients with advanced ovarian cancer
Renata R Urban, Hao He, Raphael Alfonso, et al.
Page
of 13
Search research articles
Search
Showing results (31-40 of 124) with videos related to
Sort By:
Page
of 13
Gynecologic Oncology
|
June 12, 2016
Since surgery isn't getting any easier, why is reimbursement going down? An update from the SGO taskforce on coding and reimbursement
Shitanshu Uppal, Mark S Shahin, Jill A Rathbun, et al.
Journal of Gynecologic Oncology
|
June 23, 2016
Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
Jovana Y Martin, Renata R Urban, John B Liao, et al.
Gynecologic Oncology
|
October 4, 2016
SGO Health Policy and Socioeconomic Committee: Current and Future Efforts of the Coding and Reimbursement Taskforce and the Policy, Quality and Outcomes Taskforce
Barbara A Goff, Mark S Shahin, Matthew A Powell, et al.
JAMA
|
June 10, 2004
Frequency of symptoms of ovarian cancer in women presenting to primary care clinics
Barbara A Goff, Lynn S Mandel, Cindy H Melancon, et al.
Journal of Minimally Invasive Gynecology
|
January 24, 2018
Robotic, Laparoscopic, or Open Hysterectomy: Surgical Outcomes by Approach in Endometrial Cancer
Tiffany L Beck, Melissa A Schiff, Barbara A Goff, et al.
Gynecologic Oncology
|
April 13, 2011
Patterns of spread and recurrence of sex cord-stromal tumors of the ovary
Melissa M Thrall, Pamela Paley, Ellen Pizer, et al.
American Journal of Obstetrics and Gynecology
|
June 26, 2003
Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602)
Barbara A Goff, Tove Thompson, Benjamin E Greer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 22, 2016
Evaluation of a Validated Biomarker Test in Combination With a Symptom Index to Predict Ovarian Malignancy
Renata R Urban, Alan Smith, Kathy Agnew, et al.
Integrative Cancer Therapies
|
April 30, 2013
Adverse events associated with complementary and alternative medicine use in ovarian cancer patients
Erin S Sweet, Leanna J Standish, Barbara A Goff, et al.
Gynecologic Oncology
|
December 7, 2017
The end of life costs for Medicare patients with advanced ovarian cancer
Renata R Urban, Hao He, Raphael Alfonso, et al.
Page
of 13